Copyright
©The Author(s) 2025.
World J Diabetes. Jun 15, 2025; 16(6): 103685
Published online Jun 15, 2025. doi: 10.4239/wjd.v16.i6.103685
Published online Jun 15, 2025. doi: 10.4239/wjd.v16.i6.103685
Figure 5 Metabolic parameters in type 2 diabetic mice.
A: Glycated hemoglobin (%); B: Plasma insulin concentration (μIU/mL); C: Total cholesterol (mmol/L); D: Triglyceride (mmol/L); E: Low-density lipoprotein cholesterol (mmol/L); F: High-density lipoprotein cholesterol (mmol/L). Bar charts represent the mean ± SEM, n = 8. cP < 0.001 vs control group; dP < 0.05 vs model group; eP < 0.01 vs model group; fP < 0.001 vs model group; HbA1c: Glycated hemoglobin; TC: Total cholesterol; TG: Triglyceride; LDL-C: Low-density lipoprotein cholesterol; HDL-C: High-density lipoprotein cholesterol.
- Citation: Chen JH, Dai XC, Quan ZJ, Liu XY. Erianin mitigates diabetic cardiomyopathy via adenosine monophosphate-activated protein kinase-nuclear factor erythroid 2-related factor 2-heme oxygenase-1 pathway activation. World J Diabetes 2025; 16(6): 103685
- URL: https://www.wjgnet.com/1948-9358/full/v16/i6/103685.htm
- DOI: https://dx.doi.org/10.4239/wjd.v16.i6.103685